Olivia Le Saux

7PUBLICATIONS
66CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 11, 2025
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy.

Olivia Le Saux, Renaud Sabatier, Isabelle Treilleux

|Jun 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Edith Borcoman, Bastien Cabarrou, Miguel Francisco

|May 16, 2025
Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial.

Laetitia Collet, Maude Ardin, David Venet

|Aug 26, 2024
PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma.

Sarah Spear, Olivia Le Saux, Hasan B Mirza

|Jul 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.

Olivia Le Saux, Maude Ardin, Justine Berthet

|Jul 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.

Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler

Pageof 2

Frequent Collaborators

3 joint publications

Isabelle Ray-Coquard

2 joint publications

Marie-Ange Mouret-Reynier

2 joint publications

Frédéric Selle

1 joint publications

Nicolas Cloarec